Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences, Inc. (Nasdaq: PLSE) generates frequent news as it advances its proprietary nPulse nanosecond pulsed field ablation (nsPFA) technology across cardiac and soft tissue applications. The company’s updates focus on clinical trial progress, regulatory milestones, scientific data presentations and early commercial activity for its nsPFA-based systems.
Investors and clinicians following PLSE news will see announcements on key atrial fibrillation programs, including the nPulse Cardiac Surgical System and the nPulse Cardiac Catheter Ablation System. Company releases describe IDE approvals from the U.S. Food and Drug Administration, enrollment of patients in the NANOCLAMP AF and NANOPULSE-AF studies, and feasibility results from European centers using surgical and catheter-based nsPFA devices. Late-breaking data presentations at major cardiology and cardiothoracic surgery meetings are also highlighted.
News flow also covers soft tissue ablation initiatives, such as the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules and research collaborations with academic centers on benign and malignant thyroid tumors. Pulse Biosciences reports publication of first-in-human thyroid data, IDE approvals for thyroid studies, and progress in multi-center trials like PRECISE-BTN.
In addition, PLSE news includes quarterly business updates and financial results, inducement equity grants under Nasdaq rules, and participation in healthcare investor conferences. These items provide context on the company’s operating plans, clinical strategy and capital markets activity. For readers tracking the development of nsPFA technology in atrial fibrillation and thyroid or other soft tissue indications, the Pulse Biosciences news page offers a consolidated view of company disclosures, clinical milestones and corporate events over time.
Pulse Biosciences (Nasdaq: PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its participation in two upcoming investor conferences. The company will attend the 9th Annual Needham MedTech & Diagnostics 1x1 Conference virtually on August 13, 2024, hosting one-on-one meetings without a formal presentation. Additionally, Pulse Biosciences management will present at the Canaccord Genuity Annual Growth Conference in Boston on August 14, 2024, at 8:00am ET. A live and recorded webcast of the Canaccord presentation will be available on the company's investor relations website.
Pulse Biosciences (Nasdaq: PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its plans to release second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. The company will host a conference call at 1:30pm PT / 4:30pm ET on the same day to discuss the results. Investors can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international). A live and recorded webcast of the event will also be available on the company's investor relations website.
Pulse Biosciences has received FDA Breakthrough Device Designation for its CellFX® nsPFA Cardiac Surgery System, intended for treating atrial fibrillation (AF). The system uses proprietary nanosecond Pulsed Field Ablation™ technology, featuring a surgical clamp that delivers rapid, consistent ablation lesions during cardiac procedures. This approach is significantly faster and potentially safer than current thermal ablation methods, minimizing risk to surrounding tissues.
The designation facilitates expedited development and review processes by the FDA. Pulse Biosciences plans to pursue Premarket Approval (PMA) for commercialization in the U.S. and expects to start its pivotal clinical trial in 2025, with initial human procedures slated for later this year in the Netherlands.
This milestone underscores the technology's promise as a safer and more effective AF treatment, aiming for faster market introduction and improved patient outcomes.
Pulse Biosciences has announced the successful closing of its rights offering, raising $60 million. This offering saw basic and over-subscriptions totaling $83 million, far exceeding the $60 million limit. Over 800 accounts participated, including Executive Chairman Robert Duggan. The rights offering involved the sale of six million units at $10 each, each unit comprising one share of common stock and two warrants. These warrants, exercisable at $11 per share, could potentially bring in an additional $66 million. Half of the warrants are redeemable if the stock trades above $16.50, and the other half if it exceeds $22.00 for twenty days. The funds are set to support product and clinical development, regulatory submissions, and commercial readiness of three leading CellFX nsPFA products. The company now has 61.23 million shares outstanding, excluding the warrants.
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced the preliminary results of its rights offering, which concluded on June 26, 2024. The offering, oversubscribed by 138%, is expected to generate $60 million in immediate gross proceeds, with potential additional proceeds of up to $66 million from warrant exercises. Each Unit in the $10.00 per Unit offering included one share of common stock and two warrants, with warrants exercisable at $11.00 per share and redeemable under certain conditions. Over 800 accounts participated, including the Company's Executive Chairman, Robert Duggan. The final proceeds and securities distribution will be confirmed upon the closing of the offering.
Pulse Biosciences has commenced a rights offering of up to $60 million in units. Each unit comprises one share of common stock and two warrants to purchase additional shares. The subscription rights, distributed to holders as of May 31, 2024, expire on June 26, 2024. The units are priced at the lesser of $10 per unit or the volume-weighted average price over ten trading days up to the expiration date. The warrants are exercisable immediately and valid for five years. The rights offering includes an over-subscription option, allowing shareholders to buy extra units if available. This offering adheres to the company's SEC registration currently in effect.
Pulse Biosciences announced an updated record date for its rights offering to raise up to $60 million. The new record date is May 31, 2024, replacing the original May 16, 2024. This offering allows stockholders to purchase up to 6 million units at a price of either $10 or the volume weighted average price over the ten days preceding the expiration date, June 26, 2024. Each unit includes one share of Common Stock and two warrants. If fully subscribed, the offering will provide gross proceeds of $60 million minus expenses. The Registration Statement is effective, and all details can be found on the SEC’s website.
Pulse Biosciences' CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology will be featured in several presentations at the Heart Rhythm Society 2024 Annual Meeting in Boston, MA, from May 16-19. The technology will be highlighted in six presentations and abstracts, including a live case presentation.
The preclinical and initial clinical results for CellFX nsPFA have shown promise, particularly in treating atrial fibrillation. The presentations will cover various aspects of the technology, including preclinical evaluations, first-in-human experiences, and novel catheter designs.
Prominent sessions include a live case demonstrating PVI+ with nsPFA, a presentation on the biophysical insights of novel ablation technologies, and multiple poster sessions on preclinical and clinical assessments of the technology.
Pulse Biosciences (Nasdaq: PLSE) has appointed Burke T. Barrett as President and CEO, replacing Kevin Danahy, who will become Chief Commercial Officer. Barrett brings over 35 years of experience in the medical device sector, including leadership roles at CardioFocus, Cyberkinetics, and Cyberonics. The leadership changes aim to support the company’s next growth phase, particularly the launch of its FDA-cleared CellFX nsPFA Percutaneous Electrode System. Barrett has been granted options to purchase 1.4 million shares at $7.45 per share, subject to vesting over four years and market capitalization milestones.
Pulse Biosciences, Inc. (PLSE) announced the first U.S. procedure using the CellFX nsPFA Percutaneous Electrode System after FDA clearance. The successful case marks a significant milestone in the company's pilot program, showing promising results in treating soft tissue without damaging noncellular structures. The innovative technology aims to revolutionize patient care with minimal pain and no need for general anesthesia. The company is looking forward to expanding the procedure's usage in 2024, following successful trials in Italy.